---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266973"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:23:58.203139+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M

## Summary
- Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
- GAAP net loss $5.5M vs net income $0.9M in Q3 2024; GAAP gross margin 53% vs 56%.
- Adjusted EBITDA $2.5M vs $7.6M in prior year; ex-investment income $0.5M vs $5.7M.
- Recurring revenue up 19% YoY; biopharma/CRO revenue up 14% YoY.
- FY2025 revenue guidance reaffirmed $196M-$205M (-2% to +2% growth).

## SEC filing metadata
- accession: 0001193125-25-266973
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/0001193125-25-266973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312525266973/d161249d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266973
- JSON: https://secwatch.observer/filing/0001193125-25-266973.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.